de Visser J, Coert A, Feenstra H, van der Vies J
Arzneimittelforschung. 1984;34(9):1010-7.
A novel steroid, (7 alpha, 17 alpha)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (Org OD 14), is described which has concomitant weak estrogenic, progestational and androgenic activities. This hormonal profile was demonstrated using various endocrinological tests and the results were evaluated in terms of well-known reference compounds. It has been well established that combinations of estrogens, androgens and progestagens exert positive or synergistic effects on certain target organs, e.g. the hypothalamic-pituitary axis, and antagonistic or complementary effects on others, e.g. on the endometrium. Org OD 14 with estrogenic, androgenic and progestational activities can therefore be expected to induce complex effects on various target organs. This explains the observed effects of the compound on hypothalamic-pituitary axis, bone-loss, endometrium and sexual behaviour.
描述了一种新型甾体,即(7α,17α)-17-羟基-7-甲基-19-去甲孕-5(10)-烯-20-炔-3-酮(Org OD 14),它同时具有微弱的雌激素、孕激素和雄激素活性。使用各种内分泌学测试证明了这种激素特征,并根据知名参考化合物对结果进行了评估。众所周知,雌激素、雄激素和孕激素的组合对某些靶器官,如下丘脑-垂体轴,发挥正向或协同作用,而对其他靶器官,如子宫内膜,则发挥拮抗或互补作用。因此,具有雌激素、雄激素和孕激素活性的Org OD 14有望对各种靶器官产生复杂的影响。这就解释了该化合物对下丘脑-垂体轴、骨质流失、子宫内膜和性行为所观察到的影响。